Raynaud's phenomenon: A brief review of the underlying mechanisms
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media S.A.
Abstract
Raynaud's phenomenon (RP) is characterized by exaggerated cold-induced vasoconstriction. This augmented vasoconstriction occurs by virtue of a reflex response to cooling via the sympathetic nervous system as well as by local activation of a2C adrenoceptors (a2C-AR). In a cold-initiated, mitochondrion-mediated mechanism involving reactive oxygen species and the Rho/ROCK pathway, cytoskeletal rearrangement in vascular smooth muscle cells orchestrates the translocation of a2C-AR to the cell membrane, where this receptor readily interacts with its ligand. Different parameters are involved in this spatial and functional rescue of a2C-AR. Of notable relevance is the female hormone, 17ß-estradiol, or estrogen. This is consistent with the high prevalence of RP in premenopausal women compared to age-matched males. In addition to dissecting the role of these various players, the contribution of pollution as well as genetic background to the onset and prevalence of RP are also discussed. Different therapeutic approaches employed as treatment modalities for this disease are also highlighted and analyzed. The lack of an appropriate animal model for RP mandates that more efforts be undertaken in order to better understand and eventually treat this disease. Although several lines of treatment are utilized, it is important to note that precaution is often effective in reducing severity or frequency of RP attacks. © 2016 Fardoun, Nassif, Issa, Baydoun and Eid.
Description
Keywords
Alpha 2-adrenergic receptors, Estrogen, Peripheral vascular disease, Raynaud's phenomenon, Rho kinase, Thermoregulation, Alpha 2 adrenergic receptor blocking agent, Amlodipine, Atenolol, Beraprost, Botulinum toxin a, Captopril, Carboplatin, Cisplatin, Cyclophosphamide, Dazoxiben, Doxorubicin, Enalapril, Felodipine, Gemcitabine, Ginkgo biloba extract, Ketanserin, Losartan, Metoprolol, Moxisylyte, Opc 28326, Orm 12741, Oxprenolol, Propranolol, Prostanoid, Quinapril, Udenafil, Unclassified drug, Unindexed drug, Vardenafil, Vinblastine, Yohimbine, Acroosteolysis, Actin filament, Angiography, Article, Bladder cancer, Cell communication, Disease association, Disease course, Disease exacerbation, Disease predisposition, Disease severity, Drug efficacy, Drug safety, Electroacupuncture, Finger ulcer, Genetic predisposition, Hand stripping, Hand surgery, Human, Immunocytochemistry, Meta analysis (topic), Mitochondrion, Molecular docking, Nerve stimulation, Nonhuman, Open study, Pathophysiology, Phase 2 clinical trial (topic), Pilot study, Premenopause, Prevalence, Prospective study, Protein expression, Protein function, Randomized controlled trial (topic), Raynaud phenomenon, Scleroderma, Signal transduction, Smoking, Sympathectomy, Systematic review (topic), Systemic sclerosis, Thoracic sympathectomy, Vascular smooth muscle cell, Vasoconstriction